Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 6 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Fennec Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 4 insiders, $1.51M in total
- Insiders trading
- 4
- Net value
- −$1.51M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Fennec Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Brughera Marco Maria | Director | 0 | Sep 16, 2026 | 2 |
| Raykov Rosty | Other: Former Director | 124,411 | Sep 1, 2026 | 18 |
| Sayad Pierre Sargis | Chief Medical Officer | 9,519 | Aug 31, 2026 | 6 |
| Evans Terry L | Chief Commercial Officer | 21,519 | Aug 31, 2026 | 6 |
| Cioffi Christiana Marie | Chief Strategy Officer | 24,644 | Aug 31, 2026 | 7 |
| Hackman Jeffrey S. | Chief Executive Officer | 66,302 | Aug 31, 2026 | 7 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | 241,306 | Aug 31, 2026 | 18 |
| Rallis Chris A | Director | 63,077 | Jun 10, 2026 | 3 |
| Islam Khalid | Director | 213,825 | Jun 10, 2026 | 1 |
| Cook Jodi A | Director | – | Jun 10, 2026 | 1 |
| Southpoint Capital Advisors LP | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Southpoint GP, LP | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Southpoint Capital Advisors LLC | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Southpoint GP, LLC | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Clark John Smith II | 10% Owner | 2,744,741Indirect | Dec 29, 2025 | 4 |
| Haigh Adrian | CHIEF OPERATING OFFICER | 44,444 | May 21, 2024 | 0 |
| Goel Shubh | Chief Commercial Officer | – | Dec 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 2025 (view filing) | Oct 6 | Same day | Raykov RostyDirector | SSale | −10.0K | $9.78 | −$97.8K | −10.8%82.5K after | 10b5-1 |
| Oct 9, 2025 (view filing)5:31 PM ET | Oct 7-9 | 2 days | Southpoint Capital Advisors LP and 4 others10% Owner | SSale | −67.1K | $9.48 | −$636.2K | −1.6%4.01M after | 3 lots |
| Oct 14, 2025 (view filing) | Oct 10 | 4 days | Rallis Chris ADirector | SSale | −1.77K | $9.24 | −$16.4K | −3.0%57.1K after | 10b5-1 |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Raykov RostyDirector | SSale | −10.0K | $8.10 | −$81.0K | −10.8%82.3K after | 10b5-1 |
| Nov 17, 2025 (view filing)8:42 PM ET | Nov 14-17 | 3 days | Southpoint Capital Advisors LP and 4 others10% Owner | SSale | −246.0K | $8.27 | −$2.04M | −6.1%3.76M after | 2 lots |
| Nov 20, 2025 (view filing)4:07 PM ET | Nov 18 | 2 days | Southpoint Capital Advisors LP and 4 others10% Owner | SSale | −19.3K | $8.79 | −$170.0K | −0.5%3.74M after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Raykov RostyDirector | SSale | −10.0K | $7.54 | −$75.4K | −11.4%77.5K after | 10b5-1 |
| Dec 29, 2025 (view filing)4:34 PM ET | Dec 24 | 5 days | Southpoint Capital Advisors LP and 4 others10% Owner | SSale | −1.00M | $7.50 | −$7.50M | −26.7%2.74M after | |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Raykov RostyDirector | SSale | −10.3K | $7.60 | −$78.4K | −10.5%88.0K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Raykov RostyDirector | SSale | −10.3K | $7.76 | −$80.3K | −9.5%98.5K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Raykov RostyDirector | SSale | −10.1K | $8.36 | −$84.3K | −8.8%104.0K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Raykov RostyDirector | SSale | −10.9K | $6.31 | −$69.1K | −8.8%113.9K after | 10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Raykov RostyDirector | SSale | −10.8K | $6.47 | −$69.8K | −8.2%121.5K after | 10b5-1 |
| May 12, 2026 (view filing) | May 11 | 1 day | Rallis Chris ADirector | SSale | −8.35K | $7.04 | −$58.8K | −11.7%63.1K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Raykov RostyDirector | SSale | −9.75K | $9.62 | −$93.8K | −7.0%130.1K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:05 PM ET | Jul 1 | 1 day | Raykov RostyOther: Former Director | SSale | −9.60K | $10.41 | −$99.9K | −6.5%138.9K after | 10b5-1 |
| Aug 4, 2026 (view filing)4:05 PM ET | Aug 3 | 1 day | Raykov RostyOther: Former Director | SSale | −10.0K | $9.58 | −$95.8K | −7.1%131.6K after | 10b5-1 |
| Aug 28, 2026 (view filing)5:42 PM ET | Aug 27 | 1 day | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −75.0K | $11.78 | −$883.5K | −25.6%217.7K after | 10b5-1 |
| Aug 31, 2026 (view filing)8:15 PM ET | Aug 31 | Same day | Sayad Pierre SargisChief Medical Officer | SSale | −12.0K | $12.18 | −$146.2K | −55.8%9.52K after | |
| Sep 1, 2026 (view filing)4:05 PM ET | Sep 1 | Same day | Raykov RostyOther: Former Director | SSale | −10.0K | $12.11 | −$121.1K | −7.4%124.4K after | 10b5-1 |
| Sep 16, 2026 (view filing)4:05 PM ET | Sep 15 | 1 day | Brughera Marco MariaDirector | SSale | −15.5K | $10.29 | −$160.0K | −100.0%0 after | 10b5-1 |